Vorinostat Fine Powder
NDC Package 65392-3102-0

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Vorinostat Fine powders is vorinostat is used to treat a certain type of cancer (CTCL-cutaneous T-cell lymphoma). This formulation utilizes a powder delivery system. Marketed by Curia New York, Inc., this product is identified by NDC 65392-3102.

Identification & Billing

NDC Package Code
65392-3102-0
Package Description
55 kg in 1 DRUM
Product Code
65392-3102
11-Digit Billing Format
65392310200

Clinical Specifications

Proprietary Name
Vorinostat Fine
Non-Proprietary Name
Vorinostat Fine
Substance Name
Vorinostat
Dosage Form
Powder - An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.
Active Ingredient(s)
VORINOSTAT 55 kg/55kg
Usage Information
Vorinostat is used to treat a certain type of cancer (CTCL-cutaneous T-cell lymphoma). It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Curia New York, Inc.
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING - A category specifying that a bulk product is intended for use on humans and requires a prescription.
Start Marketing Date
10-06-2006
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 65392-3102-0 identifies a specific commercial package of 55 kg in 1 drum of Vorinostat Fine (UNFINISHED drug), a bulk ingredient labeled by Curia New York, Inc.. This powder is formulated for use and contains vorinostat as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Curia New York, Inc. on October 06, 2006. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Vorinostat is used to treat a certain type of cancer (CTCL-cutaneous T-cell lymphoma). It works by slowing or stopping the growth of cancer cells.

How is this Curia New York, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 65392310200. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
65392-3102-0
11-Digit CMS (5-4-2)
65392-3102-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.